CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have been given a consensus recommendation of “Moderate Buy” by the nineteen brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation, ten have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $67.7778.

A number of brokerages recently commented on CRSP. TD Cowen lifted their price objective on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a research report on Friday, February 13th. Needham & Company LLC lifted their price objective on CRISPR Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, February 13th. Evercore reiterated an “outperform” rating and issued a $76.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, May 11th. Citigroup reiterated a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Wednesday, May 27th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $110.00 price objective (up from $105.00) on shares of CRISPR Therapeutics in a research report on Tuesday, March 17th.

Insider Buying and Selling

In related news, General Counsel James R. Kasinger sold 3,182 shares of CRISPR Therapeutics stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $46.78, for a total value of $148,853.96. Following the completion of the sale, the general counsel directly owned 94,308 shares in the company, valued at $4,411,728.24. This trade represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Samarth Kulkarni sold 10,020 shares of the business’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $46.78, for a total value of $468,735.60. Following the transaction, the chief executive officer owned 255,501 shares of the company’s stock, valued at $11,952,336.78. The trade was a 3.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 33,937 shares of company stock worth $1,646,126 over the last three months. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Several institutional investors have recently modified their holdings of CRSP. Mcguire Capital Advisors Inc. acquired a new position in shares of CRISPR Therapeutics during the 4th quarter worth about $25,000. Ramirez Asset Management Inc. acquired a new position in shares of CRISPR Therapeutics during the 4th quarter worth about $26,000. Rothschild Investment LLC grew its position in shares of CRISPR Therapeutics by 836.7% during the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after buying an additional 502 shares during the period. Thurston Springer Miller Herd & Titak Inc. grew its position in shares of CRISPR Therapeutics by 196.9% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock worth $30,000 after buying an additional 382 shares during the period. Finally, Optiver Holding B.V. grew its position in shares of CRISPR Therapeutics by 71.4% during the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after buying an additional 210 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock opened at $49.80 on Friday. The stock has a 50-day simple moving average of $52.40 and a 200 day simple moving average of $53.09. The company has a quick ratio of 17.96, a current ratio of 17.97 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $4.80 billion, a price-to-earnings ratio of -8.01 and a beta of 1.74. CRISPR Therapeutics has a 12-month low of $40.00 and a 12-month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. The firm had revenue of $1.46 million during the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%. On average, research analysts anticipate that CRISPR Therapeutics will post -4.9 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.